Technology | April 24, 2012

FDA Clears Needle Guidance System for Liver Interventions

April 24, 2012 —ActiViews Inc. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its flagship product, CT-Guide Needle Guidance System, for liver interventions.

CT-Guide navigation is designed to assist physicians during computed tomography- (CT) guided interventional diagnostic and therapeutic procedures such as percutaneous biopsies, ablations and marker placements in the lung and liver. The system enables physicians to locate interventional instruments in relation to pre-acquired CT images, which is analogous to the way a GPS locates a car using stored roadmaps. CT-Guide navigation features a single-use miniature video camera that is easily affixed onto standard interventional instruments, a patented sterile registration sticker and proprietary 3-D software viewable on a high-definition (HD) flat panel monitor mounted on a mobile workstation. CT-Guide navigation allows physicians to determine the location of the navigated instrument in relation to the 3-D space of the CT images and the desired target, continuously displaying the location of the instrument and its planned path on the CT image of the patient’s anatomy.

“With [this] announcement, ActiViews further cements our commitment to become a leading provider of minimally invasive thoracic and abdominal surgical oncology solutions,” said Christopher von Jako, ActiViews president. “With now our second successful clinical trial for the FDA with CT-Guide navigation, we are able to offer our customers an expanded indication from lung into liver and further clinical evidence of the efficacy of our unique and simple tool in these critical applications.”

In support of its FDA medical device submission for liver interventions, ActiViews concluded a safety and effectiveness clinical trial in December at two hospitals affiliated with McGill University Health Center in Montreal, Canada. The clinical study yielded 100 percent success in the primary endpoint of targeting accuracy with CT-Guide navigation used in biopsy and radiofrequency and microwave ablation procedures, and there were no device-related adverse events.

"With our experience in over 150 procedures performed at our institution, we demonstrated that CT-Guide navigation is an ideal tool for various CT-guided interventional oncology applications. By being very easy-to-use and simple to learn, the ActiViews device enables even less experienced users to perform the procedures with the effectiveness and confidence of more advanced users, further enhancing the benefits of minimally invasive interventions to a wider range of patients," said David Valenti, assistant professor and head of the division of interventional radiology, McGill University Health Center, and principle investigator in the liver study.

"The simplicity and accuracy of the ActiViews system in guiding complex, deep and double angled needle approaches has been key in our adoption and repetitive usage in our minimally invasive interventional oncology procedures at McGill. Further, by eliminating most of the trial and error cycles involved in freehand guidance, the system has shown in some of our other preliminary comparative studies to shorten procedure time and reduce patient radiation exposure during the procedure," said Tatiana Cabrera, assistant professor of radiology, McGill University Health Center.

For more information: www.cancer.com, www.activiews.com

Related Content

Feature | November 16, 2018 | By Greg Freiherr
For the first time at the RSNA meeting, vendors of interventiona
Podcast | Interventional Radiology | November 16, 2018
For the first time at the RSNA meeting, vendors of interventional products will have a dedicated area in which to dis
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to
Body Vision Medical Announces Release of LungVision
Technology | Lung Cancer | October 05, 2018
Body Vision Medical, a medical device company specializing in lung cancer diagnostics, announced the launch of its...
Image Diagnostics Debuting Interventional Radiation Shield at RSNA 2018
News | Radiation Dose Management | October 03, 2018
Image Diagnostics has entered into a product development agreement with ECLS Inc. to design a new radiation shield...
Leica Biosystems Launches MammoPort Specimen Containment and Transport System
Technology | Breast Biopsy Systems | October 03, 2018
Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system...
News | Radiation Dose Management | September 24, 2018
AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company...